OPTIONS X
28 August - 01 September 2019
1 Raffles Blvd, Singapore 039593

Abstract Submission is closed

Theme(s) and Topics

1. OPTIONS X
Topics
Virology and Pathogenesis: Viral Replication
Virology and Pathogenesis: Cellular & Molecular Virology
Virology and Pathogenesis: Emerging Influenza Viruses
Virology and Pathogenesis: Host-Pathogen Interactions
Virology and Pathogenesis: Immune Response to Infection
Virology and Pathogenesis: Influenza Evolution & Human Ecology
Virology and Pathogenesis: Influenza Glycobiology
Virology and Pathogenesis: NextGen/Universal Vaccines
Virology and Pathogenesis: Non-Human Influenza Viruses
Virology and Pathogenesis: Virus Pathogenesis & Transmission
Clinical Sciences: Avian & Zoonotic Influenza - Human Infections
Clinical Sciences: Clinical Trials - Treatment and Prevention
Clinical Sciences: Diagnostics and Disease Markers
Clinical Sciences: Special Populations
Clinical Sciences: Therapeutics – Antivirals
Clinical Sciences: Therapeutics – Immunomodulators, Supportive Care, Others
Clinical Sciences: Clinical Trials – Study Designs, Clinical Endpoints
Clinical Sciences: Clinical Trials – Vaccines
Clinical Sciences: Non-pharmaceutical Interventions – Clinical Aspects
Clinical Sciences: Development of Human Disease
Public Health: Disease Burden & Severity
Public Health: Epidemiology & Transmission
Public Health: Pandemic Preparedness
Public Health: Human Sero-Epidemiology Studies
Public Health: Surveillance & Forecasting
Public Health: Vaccine Effectiveness/Impact
Public Health: Non-Pharmaceutical Interventions – Public health aspects
Public Health: Pharmaco-ecomonics, Cost-Effectiveness Studies
Co-Infection: Co-infection models
Co-Infection: Bacterial Co-infections with Influenza
Co-Infection: Viral Coinfections with Influenza
2. OPTIONS X - LATE BREAKER
Topics
Virology and Pathogenesis: Viral Replication
Virology and Pathogenesis: Cellular & Molecular Virology
Virology and Pathogenesis: Emerging Influenza Viruses
Virology and Pathogenesis: Host-Pathogen Interactions
Virology and Pathogenesis: Immune Response to Infection
Virology and Pathogenesis: Influenza Evolution & Human Ecology
Virology and Pathogenesis: Influenza Glycobiology
Virology and Pathogenesis: NextGen/Universal Vaccines
Virology and Pathogenesis: Non-Human Influenza Viruses
Virology and Pathogenesis: Virus Pathogenesis & Transmission
Clinical Sciences: Avian & Zoonotic Influenza - Human Infections
Clinical Sciences: Clinical Trials - Treatment and Prevention
Clinical Sciences: Diagnostics and Disease Markers
Clinical Sciences: Special Populations
Clinical Sciences: Therapeutics – Antivirals
Clinical Sciences: Therapeutics – Immunomodulators, Supportive Care, Others
Clinical Sciences: Clinical Trials – Study Designs, Clinical Endpoints
Clinical Sciences: Clinical Trials – Vaccines
Clinical Sciences: Non-pharmaceutical Interventions – Clinical Aspects
Clinical Sciences: Development of Human Disease
Public Health: Disease Burden & Severity
Public Health: Epidemiology & Transmission
Public Health: Pandemic Preparedness
Public Health: Human Sero-Epidemiology Studies
Public Health: Surveillance & Forecasting
Public Health: Vaccine Effectiveness/Impact
Public Health: Non-Pharmaceutical Interventions – Public health aspects
Public Health: Pharmaco-ecomonics, Cost-Effectiveness Studies
Co-Infection: Co-infection models
Co-Infection: Bacterial Co-infections with Influenza
Co-Infection: Viral Coinfections with Influenza

View Terms and Conditions

Abstract Submission Terms and Conditions

 

By submitting an abstract, you agree to the following:

 

  1. All abstracts must be submitted in English and via the online submission site. Other forms of submission will NOT be accepted.

 

  1. All abstracts MUST be structured to include: Introduction and objectives, Methodology, Results and Conclusion.

 

  1. All relevant information must be included for an abstract to be considered. The abstract will be assessed based on the scientific merit of the study as presented in the abstract. Lack of clarity in the results will adversely affect the abstract evaluation.

 

  1. The acceptance of an abstract does not imply provision of travel, accommodation or registration for the Conference, nor any other costs associated with the preparation or presentation of the abstract, or any costs associated with attendance at the Conference.

 

  1. You must confirm that all authors, where relevant, have approved the submission.

 

  1. All authors presenting at the Conference must be paid registrants. At least one of the named authors on the abstract must register to attend the Conference to present the abstract if selected for the programme. The author(s) should immediately notify the Conference Secretariat if they are unable to present an abstract or if the presenting author has been changed.

 

  1. By submitting an abstract(s), you agree to give the Conference permission on behalf of all presenters to publish your abstract submission on the Conference website, in printed collaterals and online Conference materials (if there are any) if your abstract is accepted for presentation.

 

  1. Any commercial interests or associations that might pose a conflict of interest regarding any submission must be declared. If the abstract is accepted for presentation, its commercial interest or association must be declared on the title slide or the slide immediately following the title slide (for oral presentations), or prominently on the poster (for poster presentations).